{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(9)"],"submitter":["Ferrer R"],"funding":["Pfizer Inc"],"pubmed_abstract":["<h4>Introduction</h4>Treatments for serious infections caused by multidrug-resistant gram-negative bacteria, including metallo-β-lactamase-producing Enterobacterales (MBL-EB), are limited and aztreonam with avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor combination active against MBL-EB approved in Europe and approved for reimbursement by the Spanish National Health System (NHS). This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM-AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective.<h4>Methods</h4>A dynamic disease transmission model was develo"],"journal":["Infectious diseases and therapy"],"pagination":["2071-2092"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12425856"],"repository":["biostudies-literature"],"pubmed_title":["Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework."],"pmcid":["PMC12425856"],"pubmed_authors":["Nikolova S","Luque S","Zormpas E","Maroto-Diaz M","Dennis J","de Lossada A","de Ceano-Vivas MC","Gheorghe M","Broughton E","Moreno Y","Ferrer R","Martinez-Martinez L","Moya-Alarcon C"],"additional_accession":[]},"is_claimable":false,"name":"Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework.","description":"<h4>Introduction</h4>Treatments for serious infections caused by multidrug-resistant gram-negative bacteria, including metallo-β-lactamase-producing Enterobacterales (MBL-EB), are limited and aztreonam with avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor combination active against MBL-EB approved in Europe and approved for reimbursement by the Spanish National Health System (NHS). This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM-AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective.<h4>Methods</h4>A dynamic disease transmission model was develo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T02:50:34.426Z","creation":"2026-04-23T03:11:42.332Z"},"accession":"S-EPMC12425856","cross_references":{"pubmed":["40719947"],"doi":["10.1007/s40121-025-01202-6"]}}